ArticleBreast cancer (Dove Medical Press)2026

Assessing Thrombotic Risk in Patients with HR+/HER2- Breast Cancer Receiving CDK4/6 Inhibitors: Insights from Real-World Data from the Middle East.

Nada Alsuhebany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.